Announcing the winners of the Spatial Interactomics Grant 2025
Uppsala, Sweden – August 5, 2025
About the Grant Program
The Navinci Spatial Interactomics Grant offered researchers the opportunity to access our new, fully flexible, multiplex in situ proximity ligation assay technology. Winners will receive data from up to 9-plex (i.e., 8 isPLA reactions + DAPI) detection of protein-protein interactions, individual proteins and phosphorylations from a choice of 50 targets.
Announcing the Winners
We are delighted to announce that Guido van Mierlo, PhD, Assistant Professor at Radboudumc, and Piotr Wysocki, MD, PhD, Medical Oncologist at Medical University of Gdansk, have been awarded our Spatial Interactomics Grant.
Guido van Mierlo, PhD
Assistant Professor
Radboudumc, Netherlands
Dr. Guido van Mierlo is an Assistant Professor at Radboudumc, where he leads the Quantitative Systems Immunology group. His research combines proteomics, single-cell analysis, and computational tools to study how immune cells interact with cancer and autoimmune targets. Previously, he studied Biomedical Sciences at Radboud, and held postdoctoral positions at Radboud University and EPFL. Dr. van Mierlo is also a recipient of the Hypatia fellowship.
“We will use Navinci’s isPLA technology to map key protein-protein interactions that regulate T cell activity in melanoma. By examining differences in T cell engagement and checkpoint signaling across disease stages, we aim to uncover mechanisms of immune resistance and identify new prognostic markers.”
Piotr Wysocki, MD, PhD
Medical Oncologist
Medical University of Gdansk, Poland
Dr. Piotr T. Wysocki, MD, PhD, is a medical oncologist at the Department of Oncology and Radiotherapy, Medical University of Gdansk, Poland. He underwent residency training in oncology at the Maria Sklodowska-Curie National Research Institute of Oncology. He successfully defended his PhD thesis on the impact of lncRNA on carcinogenesis at the Medical University of Warsaw, and completed a postdoctoral fellowship at Johns Hopkins University, USA. His clinical and research interests focus primarily on gastrointestinal cancers (especially hepatobiliary malignancies), early-phase clinical trials, and translational research on predictive biomarkers.
“We will use Navinci’s isPLA technology to map key immune interactions that predict response to immunotherapy in biliary tract cancer. By analyzing PD-1/PD-L1 and PD-1/PD-L2 interactions, additional checkpoints, and immune cell engagement in tumors from patients treated with chemoimmunotherapy, we aim to uncover biomarkers of benefit and resistance, enabling more personalized and cost-effective use of immune checkpoint inhibitors.”
Find out more about the Spatial Interactomics Grant Program 2025 here.
About Navinci
Navinci is a Swedish biotech company specializing in developing innovative solutions for studying in situ protein expression and interactions. With a focus and a strong legacy in developing in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth.
